Related references
Note: Only part of the references are listed.Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target
Yao Wei et al.
SCIENCE IMMUNOLOGY (2021)
HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma
Yituo Xu et al.
BIOLOGICS-TARGETS & THERAPY (2021)
Burden of melanoma in China, 1990-2017: Findings from the 2017 global burden of disease study
Yan Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis
Patrick P. C. Boor et al.
BRITISH JOURNAL OF CANCER (2020)
HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Qiang-Hua Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma
Zhen Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target
Dongming Chen et al.
JOURNAL OF MEDICAL GENETICS (2019)
HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival
Han Yan et al.
CANCER LETTERS (2019)
HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
Chu-Yu Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7+ Tumor Cells
Xiaoxuan Zhuang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers
Haiying Cheng et al.
CLINICAL CANCER RESEARCH (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3
Murali Janakiram et al.
IMMUNOLOGICAL REVIEWS (2017)
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Claud Grigg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival
Pratistha Koirala et al.
SCIENTIFIC REPORTS (2016)
A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
Yanping Xiao et al.
CLINICAL CANCER RESEARCH (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function
Ruihua Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
B7-H5 costimulates human T cells via CD28H
Yuwen Zhu et al.
NATURE COMMUNICATIONS (2013)
A new understanding in the epidemiology of melanoma
Esther Erdei et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Skin cancer in skin of color
Hugh M. Gloster et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Share Paper
